Mithra Pharmaceuticals S.A. Logo

Mithra Pharmaceuticals S.A.

Biotech firm developing pharma for women's health: contraception, fertility, and menopause.

MITRA | BR

Overview

Corporate Details

ISIN(s):
BE0974283153 (+1 more)
LEI:
5493002FDD273HTEKK14
Country:
Belgium
Address:
Rue Saint-Georges 5, 4000 Liège
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mithra Pharmaceuticals S.A. is a biotechnology company dedicated to women's health. The company specializes in the development, manufacturing, and commercialization of proprietary and over-the-counter pharmaceutical products. Its core focus areas include contraception, fertility, and menopause. Mithra's mission is to transform the women's health sector by providing innovative new choices that aim to improve the overall quality of life for women.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-06-11 10:00
M&A Activity
2024-06-11_Mithra_Press-Release_Mithra sells to GR_EN-FS (003) (002)-PDF.pdf
English 179.8 KB
2024-06-11 10:00
M&A Activity
2024-06-11_Mithra_Press-Release_Mithra sells to GR_FR-FS-PDF.pdf
French 126.7 KB
2024-06-10 19:15
Legal Proceedings Report
2024-06-10_Mithra_Press-Release_Mithra files for bankruptcy AND sells to GR_EN.…
English 181.9 KB
2024-06-10 19:15
Legal Proceedings Report
2024-06-10_Mithra_Press-Release_Mithra files for bankruptcy AND sells to GR_FR.…
French 128.7 KB
2024-06-04 08:00
Legal Proceedings Report
2024-0~1.PDF
English 153.0 KB
2024-06-04 08:00
Legal Proceedings Report
2024-0~2.PDF
French 158.7 KB
2024-05-28 15:00
Pre-Annual General Meeting Information
2024-05-28_Mithra_Press-release_Mithra postpones its annual general meeting_EN.…
English 139.6 KB
2024-05-28 15:00
Pre-Annual General Meeting Information
2024-05-28_Mithra_Press-release_Mithra postpones its annual general meeting_FR.…
French 143.3 KB
2024-05-10 16:30
Regulatory Filings
2024-05-10_Mithra_Press-release_Additional patent protection NEXSTELLIS_EN.pdf
English 124.3 KB
2024-05-10 16:30
Regulatory Filings
2024-05-10_Mithra_Press-release_Additional patent protection NEXSTELLIS_FR.pdf
French 126.5 KB
2024-05-03 17:30
M&A Activity
2024-05-03_Mithra_Press-release_Mithra Announces Exclusive Negotiations and Fun…
English 142.7 KB
2024-05-03 17:30
Capital/Financing Update
2024-05-03_Mithra_Press-release_Mithra Announces Exclusive Negotiations and Fun…
French 145.9 KB
2024-04-30 10:30
Proxy Solicitation & Information Statement
2024-04-30_MITHRA_VOTING-BY-MAIL-FORM_AGO-MAY-2024_EN.pdf
English 141.0 KB
2024-04-30 10:30
Pre-Annual General Meeting Information
2024-04-30_MITHRA_AGENDA_AGO-MAY-2024_FR.pdf
French 143.1 KB
2024-04-30 10:30
Proxy Solicitation & Information Statement
2024-04-30_MITHRA_PROXY-FORM_AGO-MAY-2024_EN.pdf
English 145.2 KB

Automate Your Workflow. Get a real-time feed of all Mithra Pharmaceuticals S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mithra Pharmaceuticals S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mithra Pharmaceuticals S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-01-17 NOSHAQ SA Board Other 172,574 617,814.92 EUR
2022-11-17 NOSHAQ SA Board Other 172,574 1,052,701.40 EUR
2022-07-18 NOSHAQ SA Board Other 156,250 1,006,250.00 EUR
2022-05-13 NOSHAQ SA Board Other 156,250 1,239,062.50 EUR
2022-04-13 Gordenne Valérie Other Sell 8,500 87,380.00 EUR
2022-03-29 Fornieri Francesco Board Sell 100,000 1,312,000.00 EUR
2022-03-25 Fornieri Francesco Board Sell 35,893 486,530.57 EUR
2022-03-24 Fornieri Francesco Board Sell 15,657 219,536.19 EUR
2022-03-24 Fornieri Francesco Board Sell 2,818 39,452.00 EUR
2022-03-23 Fornieri Francesco Board Sell 12,525 178,230.75 EUR

Peer Companies

Mineralys Therapeutics, Inc. Logo
Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.
United States of America
MLYS
MiNK Therapeutics, Inc. Logo
Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.
United States of America
INKT
MIRA PHARMACEUTICALS, INC. Logo
Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.
United States of America
MIRA
Mirum Pharmaceuticals, Inc. Logo
Develops and commercializes therapies for rare, debilitating liver diseases in children and adults.
United States of America
MIRM
MIZUHO MEDY CO.,LTD. Logo
Develops rapid diagnostic tests & gene analyzers for clinical, research & agricultural markets.
Japan
4595
MOA Life Plus Co. Ltd. Logo
Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.
South Korea
142760
Moberg Pharma Logo
Develops & commercializes a leading topical treatment for nail fungus for European markets.
Sweden
MOB
Mochida Pharmaceutical Co.,Ltd. Logo
An R&D-driven company making drugs, skincare, and medical equipment for specialized fields.
Japan
4534
Moderna, Inc. Logo
Pioneering mRNA science to create transformative medicines and vaccines for diverse diseases.
United States of America
MRNA
Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
United States of America
MNPR

Talk to a Data Expert

Have a question? We'll get back to you promptly.